C07K 5/1002
With the first amino acid being neutral
Official title: {with the first amino acid being neutral}
C07K5/1002 (With the first amino acid being neutral) appears on 1,468 US grants and 1,736 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,468
- Published applications
- 1,736
- Assignees
- 977
- Inventors
- 3,973
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 12 | 0 |
| 1977 | 8 | 0 |
| 1978 | 14 | 0 |
| 1979 | 7 | 0 |
| 1980 | 17 | 0 |
| 1981 | 22 | 0 |
| 1982 | 15 | 0 |
| 1983 | 11 | 0 |
| 1984 | 15 | 0 |
| 1985 | 9 | 0 |
| 1986 | 8 | 0 |
| 1987 | 12 | 0 |
| 1988 | 7 | 0 |
| 1989 | 4 | 0 |
| 1990 | 5 | 0 |
| 1991 | 3 | 0 |
| 1992 | 12 | 0 |
| 1993 | 9 | 0 |
| 1994 | 11 | 0 |
| 1995 | 19 | 0 |
| 1996 | 21 | 0 |
| 1997 | 33 | 0 |
| 1998 | 47 | 0 |
| 1999 | 31 | 0 |
| 2000 | 33 | 0 |
| 2001 | 34 | 6 |
| 2002 | 31 | 39 |
| 2003 | 33 | 75 |
| 2004 | 34 | 71 |
| 2005 | 32 | 72 |
| 2006 | 45 | 73 |
| 2007 | 46 | 66 |
| 2008 | 37 | 70 |
| 2009 | 50 | 82 |
| 2010 | 55 | 78 |
| 2011 | 44 | 79 |
| 2012 | 49 | 79 |
| 2013 | 67 | 90 |
| 2014 | 72 | 82 |
| 2015 | 53 | 79 |
| 2016 | 72 | 69 |
| 2017 | 43 | 67 |
| 2018 | 38 | 76 |
| 2019 | 36 | 68 |
| 2020 | 38 | 74 |
| 2021 | 28 | 62 |
| 2022 | 35 | 49 |
| 2023 | 28 | 65 |
| 2024 | 35 | 69 |
| 2025 | 30 | 57 |
| 2026 | 18 | 39 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Polypeptide compound and use thereof in treatment of enteritis29 Sep 2026US 12,747,267 B2Sichuan Gooddoctor Panxi Pharmaceutical Co., Ltd.
- Aqueous peptide programming of the vinylidene fluoride ferroelectric phase29 Sep 2026US 12,747,302 B2Northwestern University
- Small molecule inhibitors of SARS-CoV-2 viral replication and uses thereof25 Aug 2026US 12,715,896 B2Arizona Board of Regents on Behalf of the University of Arizona
- Cosmetic tetrapeptide, composition and use21 Jul 2026US 12,686,703 B2Sederma
- Labyrinthin-based peptides for cancer immunotherapies and uses thereof16 Jun 2026US 12,655,184 B2LabyRx Immunologic Therapeutics (USA) Limited
- Amino acid-derived ceramide, synthesis method therefor and use thereof1 Oct 2026US 2026/0297018 A1Shenzhen Dikeman Biotechnology Co., Ltd.
- Universal abt compounds and uses thereof24 Sep 2026US 2026/0284204 A1Kleo Pharmaceuticals, Inc.
- Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives17 Sep 2026US 2026/0273017 A1Ambrx, Inc.
- ¿ opioid receptor agonist and use thereof17 Sep 2026US 2026/0274891 A1Chengdu Aoda Biotechnology Co., Ltd
- Macrocyclic broad spectrum antibiotics17 Sep 2026US 2026/0274892 A1Genentech, Inc.
Most cited
By later US patents
- Combinatorial strategies for polymer synthesis484US 5,677,195 AAffymax Technologies N.V. · 1997
- Antibody compositions for selectively inhibiting VEGF356US 6,342,219 B12002
- Combinatorial strategies for polymer synthesis277US 6,040,193 AAffymetrix, Inc. · 2000
- Peptide library and screening systems197US 5,432,018 AAffymax Technologies N.V. · 1995
- Antibody conjugate compositions for selectively inhibiting VEGF181US 6,342,221 B12002